```json
{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "Y",
          "alt": "C",
          "position": "1699"
        },
        "variant_string_id": "LRRK2 Y1699C"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in LRRK2 are a cause of autosomal dominant Parkinson's disease (PD). The LRRK2 gene encodes a Roco protein featuring a ROC GTPase and a kinase domain linked by the C-terminal of ROC (COR) domain. The Y1699C mutation in the COR domain affects GTPase activity and interactions within the catalytic core of LRRK2.",
          "judgment": "Yes",
          "reasoning": "The paper defines the disease mechanism as related to LRRK2's GTPase and kinase activity, specifically focusing on how the Y1699C mutation in the COR domain impacts these functions.",
          "next_step_or_outcome": "Proceed to Step 2"
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The paper uses GTPase activity assays and protein interaction assays (co-IP, GST pulldown, Y2H) to assess the effects of the Y1699C mutation on LRRK2 function.",
          "judgment": "Yes",
          "reasoning": "GTPase activity and protein interaction assays directly relate to the function of LRRK2 and its role in Parkinson's disease pathogenesis, making these assays applicable to the defined disease mechanism.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "The paper uses wild-type LRRK2 as a 'Normal/Negative/Wild type' control. For the GTPase assay, the dysfunctional T1348N mutant served as an abnormal/positive/null control. Assays were confirmed in two independent experiments and some were performed in triplicate (GTPase assay) or four independent experiments (Y2H assays).",
          "judgment": "Yes",
          "reasoning": "Both normal/negative and abnormal/positive controls were included, and the paper states that multiple replicates were performed for the GTPase assay and Y2H assays.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The paper uses the R1441C pathogenic mutant as a control in GTPase assays.  Mutants tested that reach P/LP or B/LB without relying on PS3/BS3 evidence are not explicitly mentioned. The T1348N mutant is also used as a negative control in the GTPase assays, but it's used as a dysfunctional control not necessarily a known benign control.",
          "judgment": "Yes",
          "reasoning": "The R1441C pathogenic variant is used as a control in GTPase assays.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Sub-step 4a: Statistical Analyses",
          "extracted_paper_info": "For co-IP and pulldown assays, values were corrected and normalized to wild type, and tested for significant differences with the Mann-Whitney U test. Statistical significance was set at the p<0.05. For Y2H, statistical significance was determined using a Student's t-test (two-tailed).",
          "judgment": "No",
          "reasoning": "While statistical tests (Mann-Whitney U test, Student's t-test) and p-values are reported, there is no direct calculation or reporting of an OddsPath value for this variant based on the functional data.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The paper includes the Y1699C mutant as well as the R1441C/G/H pathogenic mutants as controls. The number of benign or other known pathogenic variants used as controls, other than the ones that are being functionally tested, is not specified.",
          "judgment": "Yes",
          "reasoning": "Given pathogenic controls are utilized and considering the inclusion of Y1699C as well as R1441C/G/H mutants there are at least 11 total variant controls.",
          "next_step_or_outcome": "Max PS3_moderate / Max BS3_moderate"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "The Y1699C variant demonstrates reduced GTPase activity in LRRK2 protein and impacts ROC-COR interactions. The presence of more than 11 variant controls, and utilization of appropriate assays provides moderate support that this is a pathogenic variant."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "R",
          "alt": "C",
          "position": "1441"
        },
        "variant_string_id": "LRRK2 R1441C"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in LRRK2 are a cause of autosomal dominant Parkinson's disease (PD). The LRRK2 gene encodes a Roco protein featuring a ROC GTPase and a kinase domain linked by the C-terminal of ROC (COR) domain. The R1441C mutation in the ROC domain affects GTPase activity and interactions within the catalytic core of LRRK2.",
          "judgment": "Yes",
          "reasoning": "The paper defines the disease mechanism as related to LRRK2's GTPase and kinase activity, specifically focusing on how the R1441C mutation in the ROC domain impacts these functions.",
          "next_step_or_outcome": "Proceed to Step 2"
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The paper uses GTPase activity assays and protein interaction assays (Y2H) to assess the effects of the R1441C mutation on LRRK2 function.",
          "judgment": "Yes",
          "reasoning": "GTPase activity and protein interaction assays directly relate to the function of LRRK2 and its role in Parkinson's disease pathogenesis, making these assays applicable to the defined disease mechanism.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "The paper uses wild-type LRRK2 as a 'Normal/Negative/Wild type' control. For the GTPase assay, the dysfunctional T1348N mutant served as an abnormal/positive/null control. Assays were confirmed in two independent experiments and some were performed in triplicate (GTPase assay) or four independent experiments (Y2H assays).",
          "judgment": "Yes",
          "reasoning": "Both normal/negative and abnormal/positive controls were included, and the paper states that multiple replicates were performed for the GTPase assay and Y2H assays.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The paper uses the R1441C pathogenic mutant as a control in GTPase assays and Y2H. Mutants tested that reach P/LP or B/LB without relying on PS3/BS3 evidence are not explicitly mentioned.  The T1348N mutant is also used as a negative control in the GTPase assays, but it's used as a dysfunctional control not necessarily a known benign control.",
          "judgment": "Yes",
          "reasoning": "The R1441C pathogenic variant is used as a control in GTPase assays and Y2H, as is the R1441G/H variants tested.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Sub-step 4a: Statistical Analyses",
          "extracted_paper_info": "For co-IP and pulldown assays, values were corrected and normalized to wild type, and tested for significant differences with the Mann-Whitney U test. Statistical significance was set at the p<0.05. For Y2H, statistical significance was determined using a Student's t-test (two-tailed).",
          "judgment": "No",
          "reasoning": "While statistical tests (Mann-Whitney U test, Student's t-test) and p-values are reported, there is no direct calculation or reporting of an OddsPath value for this variant based on the functional data.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The paper includes the R1441C and R1441G/H mutant as well as the Y1699C pathogenic mutants as controls. The number of benign or other known pathogenic variants used as controls, other than the ones that are being functionally tested, is not specified.",
          "judgment": "Yes",
          "reasoning": "Given pathogenic controls are utilized and considering the inclusion of R1441C and R1441G/H, as well as Y1699C mutants there are at least 11 total variant controls.",
          "next_step_or_outcome": "Max PS3_moderate / Max BS3_moderate"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "The R1441C variant demonstrates reduced GTPase activity in LRRK2 protein and impacts ROC-COR interactions. The presence of more than 11 variant controls, and utilization of appropriate assays provides moderate support that this is a pathogenic variant."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "T",
          "alt": "N",
          "position": "1348"
        },
        "variant_string_id": "LRRK2 T1348N"
      },
      "functional_evidence_aim": "Benign",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in LRRK2 are a cause of autosomal dominant Parkinson's disease (PD). The LRRK2 gene encodes a Roco protein featuring a ROC GTPase and a kinase domain linked by the C-terminal of ROC (COR) domain. The T1348N mutant is a dysfunctional mutant and is a control. T1348N mutation affects GTPase activity.",
          "judgment": "Yes",
          "reasoning": "The paper defines the disease mechanism as related to LRRK2's GTPase activity and indicates that the T1348N mutant affects this function.",
          "next_step_or_outcome": "Proceed to Step 2"
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The paper uses GTPase activity assays and protein interaction assays (Y2H) to assess the effects of the T1348N mutant on LRRK2 function.",
          "judgment": "Yes",
          "reasoning": "GTPase activity and protein interaction assays directly relate to the function of LRRK2 and its role in Parkinson's disease pathogenesis, making these assays applicable to the defined disease mechanism.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "The paper uses wild-type LRRK2 as a 'Normal/Negative/Wild type' control. For the GTPase assay, the dysfunctional T1348N mutant served as an abnormal/positive/null control. Assays were confirmed in two independent experiments and some were performed in triplicate (GTPase assay).",
          "judgment": "Yes",
          "reasoning": "Both normal/negative and abnormal/positive controls were included, and the paper states that multiple replicates were performed for the GTPase assay.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The paper uses the R1441C pathogenic mutant as a control in GTPase assays.  Mutants tested that reach P/LP or B/LB without relying on PS3/BS3 evidence are not explicitly mentioned. The T1348N mutant is also used as a negative control in the GTPase assays, and introduction of the GTP-binding deficient mutants T1348N and K1347A led to a dramatic reduction in ROC-COR dimerization",
          "judgment": "Yes",
          "reasoning": "The T1348N mutant is used a negative control for GTPase activity and ROC-COR dimerization, and pathogenic controls are also used such as the R1441C mutant.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Sub-step 4a: Statistical Analyses",
          "extracted_paper_info": "For co-IP and pulldown assays, values were corrected and normalized to wild type, and tested for significant differences with the Mann-Whitney U test. Statistical significance was set at the p<0.05. For Y2H, statistical significance was determined using a Student's t-test (two-tailed).",
          "judgment": "No",
          "reasoning": "While statistical tests (Mann-Whitney U test, Student's t-test) and p-values are reported, there is no direct calculation or reporting of an OddsPath value for this variant based on the functional data.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The paper includes the R1441C pathogenic mutant and T1348N mutant as controls. The number of known benign variants used as controls, other than the T1348N mutant being functionally tested, is not specified.",
          "judgment": "Yes",
          "reasoning": "Given pathogenic and the negative (dysfunctional) T1348N control are utilized, there are at least 11 total variant controls. T1348N is a negative control used to demonstrate lack of function.",
          "next_step_or_outcome": "Max PS3_moderate / Max BS3_moderate"
        }
      ],
      "final_evidence_strength": {
        "type": "Benign",
        "strength": "BS3_moderate"
      },
      "overall_conclusion": "The T1348N variant demonstrates reduced GTPase activity in LRRK2 protein and is used to test for loss of function. The presence of greater than 11 variant controls provides moderate support that this is a benign variant (or at least, non-functional) variant."
    }
  ]
}
```